Seems the market is waiting for all or nothing with approval. These results seem very positive. Data looks solid. If you had any connection or history with this aBMT rejection, you’d be very happy that a company was making good headway with R&D.
Market shrugging for now, but this is definitely good news.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-22
-
- There are more pages in this discussion • 334 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |